PVG Asset Management Corp Invests $474,000 in Veru Inc. (NASDAQ:VERU)

PVG Asset Management Corp purchased a new position in shares of Veru Inc. (NASDAQ:VERU) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 563,155 shares of the company’s stock, valued at approximately $474,000. Veru comprises 1.9% of PVG Asset Management Corp’s holdings, making the stock its 13th biggest holding. PVG Asset Management Corp owned approximately 0.38% of Veru at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Cetera Advisors LLC acquired a new position in Veru during the first quarter worth about $33,000. Choreo LLC acquired a new position in Veru during the 1st quarter worth approximately $64,000. Rhumbline Advisers lifted its stake in Veru by 3,994.8% in the 2nd quarter. Rhumbline Advisers now owns 113,632 shares of the company’s stock valued at $96,000 after purchasing an additional 110,857 shares during the last quarter. SeaCrest Wealth Management LLC boosted its position in Veru by 313.8% in the second quarter. SeaCrest Wealth Management LLC now owns 120,000 shares of the company’s stock valued at $101,000 after buying an additional 91,000 shares in the last quarter. Finally, 180 Wealth Advisors LLC bought a new stake in shares of Veru during the first quarter worth $120,000. Institutional investors own 47.16% of the company’s stock.

Veru Price Performance

VERU opened at $0.77 on Tuesday. Veru Inc. has a fifty-two week low of $0.36 and a fifty-two week high of $1.92. The company’s 50 day moving average price is $0.85 and its two-hundred day moving average price is $0.97. The firm has a market capitalization of $112.57 million, a price-to-earnings ratio of -2.26 and a beta of -0.48.

Veru (NASDAQ:VERU) last issued its earnings results on Thursday, August 8th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). The business had revenue of $3.95 million during the quarter, compared to the consensus estimate of $3.50 million. Veru had a negative return on equity of 115.99% and a negative net margin of 376.38%. During the same quarter in the previous year, the firm posted ($0.13) earnings per share. As a group, equities research analysts predict that Veru Inc. will post -0.3 EPS for the current year.

Veru Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.